Qureight’s Vascul8 model has been validated in a peer-reviewed study marking a significant advance in the treatment of pulmonary vascular disorders.
The AI-powered imaging platform demonstrated its ability to predict disease severity and identify patients at risk of residual pulmonary hypertension (PH) following surgery for chronic thromboembolic pulmonary hypertension (CTEPH).
CTEPH is caused by persistent blood clots in the lung arteries, often treated with pulmonary endarterectomy (PEA) surgery. However, some patients continue to suffer from residual PH, typically assessed through right heart catheterisation – an invasive and costly procedure. The study showed that Vascul8 can reduce reliance on this method by accurately screening patients using routine CT scans.
Joanna Pepke-Zaba, Consultant Physician at Royal Papworth Hospital NHS Foundation Trust and lead author, said: “CTEPH has for a long time had a complex disease management pathway, requiring the subjective expertise of multidisciplinary teams. We are excited to have worked on this study where we show an alternative approach to imaging CTEPH and patient management, employing Qureight’s imaging analysis model, Vascul8. This signals a major step forward in deploying imaging in severe and complex respiratory and vascular diseases.”
Hakim Ghani, Research Fellow and first author, explained: “Powered by Vascul8, automated quantification of lung blood volumes from CT scans can help identify patients with chronic blood clots who remain at risk of residual pulmonary hypertension after surgery. This AI-driven imaging approach could guide better treatment decisions, support more personalised care, reduce the need for invasive tests, and enable new endpoints in clinical trials – overall offering huge potential for patient benefit.”
Simon Walsh, CSO at Qureight, added: “This study shows the promise of our deep-learning vascular biomarkers and demonstrates that our imaging platform can be used beyond fibrotic lung disease, in pulmonary vascular disorders such as CTEPH.”
